Regimen Reference Order – LEUK – crisantaspase (RYLAZE)

LEUK – crisantaspase is prescribed in combination with an ALL or LBL protocol

ARIA Support: LEUK - [crisantaspase (RYLAZE)]

Planned Course: **Three doses per week on Monday, Wednesday and Friday for a total of six doses to replace each planned dose of pegaspargase**

See Appendix (page 4) for regimen Dosing Schema

Indication for Use: **Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL) with hypersensitivity to E. *coli*-derived asparaginase**

CVAD: Refer to prescribed ALL or LBL protocol

Bloodwork requirements:

- ***Refer to prescribed ALL or LBL protocol***

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LEUK – crisantaspase (RYLAZE)

Drug	Dose	CCMB Administration Guideline
Three doses per week on Monday, Wednesday and Friday for 6 doses (2 weeks)		
Days 1, 3, 5, 8, 10 and 12		
cetirizine	**6 to 23 months:** 2.5 mg **2 to 5 years:** 5 mg **6 years or older:** 10 mg	Orally 30 minutes prior to crisantaspase (RYLAZE)
famotidine	**18 to 23.9 kg:** 10 mg **24 to 35.9 kg:** 15 mg **36 kg or greater:** 20 mg	Orally 30 minutes prior to crisantaspase (RYLAZE)
hydrocortisone	2 mg/kg/dose; maximum dose 100 mg	**First dose:** IV in normal saline 50 mL over 15 minutes **45 minutes** prior to crisantaspase (RYLAZE) **Nursing Alert: crisantaspase starts **45 minutes after completion** of* hydrocortisone *infusion* **Dose 2 and Onwards:** **ONLY** to be given if patient had a previously mild reaction to crisantaspase (RYLAZE). hydrocortisone to be ordered **at physician's discretion** IV in normal saline 50 mL over 15 minutes **45 minutes** prior to crisantaspase (RYLAZE)

Wait 45 minutes after completion of IV pre-medication(s) before starting crisantaspase		
crisantaspase (RYLAZE®)	**Days 1 and 8 (Mondays):** 25 mg/m^2	Intramuscular once ** Alert: Maximum volume at each injection site is 2 mL* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order* ** Nursing Alert: crisantaspase (RYLAZE) must be administered at scheduled time, as follows:* *Monday doses: 09:00* *Wednesday doses: 09:00* *Friday doses: 13:00*
	Days 3 and 10 (Wednesdays): 25 mg/m^2	
	Days 5 and 12 (Fridays): 50 mg/m^2	
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information		
crisantaspase (RYLAZE®) available dosage strength: 10 mg per 0.5 mL syringe **Classification: Cytotoxic, Hazardous**		

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

- CBC, serum creatinine, urea, electrolytes, liver enzymes, bilirubin and glucose prior to treatment and every 2 to 3 weeks as per Physician Order
- Clinical examination every 2 to 3 weeks
- Fibrinogen and lipase as per Physician Orders
- Refer to the prescribed ALL or LBL protocol for additional monitoring
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 1 hour after crisantaspase (RYLAZE®) injection. Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Refer to prescribed ALL or LBL protocol		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Refer to the prescribed ALL or LBL protocol for additional instructions
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- To maintain adequate drug levels, crisantaspase (RYLAZE®) will be scheduled on Mondays and Wednesdays at 9 am and Fridays at 1 pm
- Physician or designate must be on site in case of reactions to crisantaspase (RYLAZE®)
  - Do not administer on weekends or holidays
- crisantaspase (RYLAZE®) can cause anaphylaxis. cetirizine, hydrocortisone and EPINEPHrine must be available in case of reaction
- crisantaspase (RYLAZE®) can cause hyperglycemia
- crisantaspase (RYLAZE®) can cause serious side effects such as hemorrhage, pancreatitis, hepatotoxicity and thrombotic events
- Refer to the prescribed ALL or LBL protocol for additional information
- Support protocol is available under **crisantaspase (RYLAZE)** in the "Leukemia" folder
- Administration site restrictions are in place for crisantaspase (RYLAZE®). crisantaspase (RYLAZE®) must be administered at CCMB MacCharles in Winnipeg

Appendix A

Dosing Schema

Week	**Week 1**							**Week 2**						
Week Day	Mon	Tues	Wed	Thurs	Fri	Sat	Sun	Mon	Tues	Wed	Thurs	Friday	Sat	Sun
Day	Day 1		Day 3		Day 5			Day 8		Day 10		Day 12		
crisantaspase (RYLAZE) 25 mg/m^2 IM	■		■					■		■				
crisantaspase (RYLAZE) 50 mg/m^2 IM					■							■		

Key: ■ **Indicates that medication will be administered on this day**